BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 [Yahoo! Finance]
AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial [Yahoo! Finance]